Candidate biomarkers in heart failure with reduced and preserved ejection fraction

References

• Altin SE, Schulze PC. (2011). Fractalkine: a novel cardiac chemokine? Cardiovasc Res 92:361–2
   PubMed Web of Science ®Google Scholar
• Anand IS, Kempf T, Rector TS, et al. (2010). Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122:1387–95
   PubMed Web of Science ®Google Scholar
• Anand IS, Rector TS, Cleland JG, et al. (2011). Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569–77
   PubMed Web of Science ®Google Scholar
• Anand IS, Rector TS, Kuskowski M, et al. (2013). Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 15:511–18
   PubMed Web of Science ®Google Scholar
• Baessler A, Strack C, Rousseva E, et al. (2012). Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 14:1240–8
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, De Antonio M, Vila J, et al. (2014). Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63:158–66
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Zeller T, Saarela O, et al. (2010). Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388–97
   PubMed Web of Science ®Google Scholar
• Braga JR, Tu JV, Austin PC, et al. (2013). Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail 6:193–202
   PubMed Web of Science ®Google Scholar
• Brouwers FP, De Boer RA, van der Harst P, et al. (2013). Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34:1424–31
   PubMed Web of Science ®Google Scholar
• Brouwers FP, Hillege HL, van Gilst WH, van Veldhuisen DJ. (2012). Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. Curr Heart Fail Rep 9:363–8
   PubMedGoogle Scholar
• Chen LQ, De Lemos JA, Das SR, et al. (2013). Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 59:536–46
   PubMed Web of Science ®Google Scholar
• Cheng JM, Akkerhuis KM, Battes LC, et al. (2013). Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 15:1350–62
   PubMed Web of Science ®Google Scholar
• Coglianese EE, Larson MG, Vasan RS, et al. (2012). Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58:1673–81
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Laughlin GA, et al. (2011). Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123:2101–10
   PubMed Web of Science ®Google Scholar
• De Boer RA, Edelmann F, Cohen-Solal A, et al. (2013). Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 15:1095–101
   PubMed Web of Science ®Google Scholar
• De Boer RA, Lok DJ, Jaarsma T, et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–8
   PubMed Web of Science ®Google Scholar
• De Lemos JA, Drazner MH, Omland T, et al. (2010). Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304:2503–12
   PubMed Web of Science ®Google Scholar
• deFilippi CR, De Lemos JA, Christenson RH, et al. (2010). Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304:2494–502
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Koehler W, et al. (2012). Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit – the Linz Intensive Care Unit (LICU) study. Clin Chim Acta 413:587–93
   PubMed Web of Science ®Google Scholar
• Escher F, Vetter R, Kuhl U, et al. (2011). Fractalkine in human inflammatory cardiomyopathy. Heart 97:733--9
   Google Scholar
• Fiedler J, Batkai S, Thum T. (2014). MicroRNA-based therapy in cardiology. Herz 39:194–200
   PubMed Web of Science ®Google Scholar
• Funke-Kaiser A, Havulinna AS, Zeller T, et al. (2014a). Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med 46:155–62
   PubMed Web of Science ®Google Scholar
• Funke-Kaiser A, Mann K, Colquhoun D, et al. (2014b). Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. Int J Cardiol 172:411–18
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Januzzi JL, Jr. (2013). Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832:2442–50
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Szymonifka J, Bhardwaj A, et al. (2014). Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2:65–72
   PubMed Web of Science ®Google Scholar
• Gruson D, Lepoutre T, Ahn SA, Rousseau MF. (2014). Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol 172:e250–2
   PubMed Web of Science ®Google Scholar
• Gupta SK, Piccoli MT, Thum T. (2014). Non-coding RNAs in cardiovascular ageing. Ageing Res Rev 17C:79–85
   Google Scholar
• Heger J, Schiegnitz E, von Waldthausen D, et al. (2010). Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 224:120–6
   PubMed Web of Science ®Google Scholar
• Heymans S, Schroen B, Vermeersch P, et al. (2005). Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112:1136–44
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK, et al. (2009). Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–16
   PubMed Web of Science ®Google Scholar
• Ho JE, Larson MG, Ghorbani A, et al. (2013). Soluble ST2 predicts elevated SBP in the community. J Hypertens 31:1431–6
   PubMed Web of Science ®Google Scholar
• Ho JE, Liu C, Lyass A, et al. (2012). Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60:1249–56
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–54
   PubMed Web of Science ®Google Scholar
• Jungbauer CG, Riedlinger J, Block D, et al. (2014). Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark Med 8:777–89
   PubMed Web of Science ®Google Scholar
• Kempf T, Zarbock A, Widera C, et al. (2011). GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581–8
   PubMed Web of Science ®Google Scholar
• Kohli P, Bonaca MP, Kakkar R, et al. (2012). Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 58:257–66
   PubMed Web of Science ®Google Scholar
• Koller L, Blum S, Korpak M, et al. (2014). Predictive power of the fractalkine receptor CX3CR1 on CD4 T cells in patients with chronic heart failure. Int J Cardiol 171:96–7
   PubMed Web of Science ®Google Scholar
• Komajda M. (2012). Management of heart failure: a challenge for healthcare systems. Bull Acad Natl Med 196:1159–65; discussion 1165–7
   PubMed Web of Science ®Google Scholar
• Komajda M, Lam CS. (2014). Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022–32
   PubMed Web of Science ®Google Scholar
• Kumarswamy R, Bauters C, Volkmann I, et al. (2014). The circulating long non-coding RNA LIPCAR predicts survival in heart failure patients. Circ Res 114:1569–75
   PubMed Web of Science ®Google Scholar
• Kumarswamy R, Thum T. (2013). Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 113:676–89
   PubMed Web of Science ®Google Scholar
• Ky B, French B, McCloskey K, et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4:180–7
   PubMed Web of Science ®Google Scholar
• Liew FY, Pitman NI, McInnes IB. (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10:103–10
   PubMed Web of Science ®Google Scholar
• Lin DC, Diamandis EP, Januzzi JL Jr, et al. (2014). Natriuretic peptides in heart failure. Clin Chem 60:1040–6
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. (2010). Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55:2062–76
   PubMed Web of Science ®Google Scholar
• Masson S, Anand I, Favero C, et al. (2012). Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125:280–8
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–847
   PubMed Web of Science ®Google Scholar
• Motiwala SR, Szymonifka J, Belcher A, et al. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15:1157–63
   PubMed Web of Science ®Google Scholar
• Nair N, Kumar S, Gongora E, Gupta S. (2013). Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 376:33–40
   PubMed Web of Science ®Google Scholar
• Neumann JT, Tzikas S, Funke-Kaiser A, et al. (2013). Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis 228:451–9
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C, Sanderson JE, et al. (2007). How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–50
   PubMed Web of Science ®Google Scholar
• Richter B, Koller L, Hohensinner PJ, et al. (2012). Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 108:1220–7
   PubMed Web of Science ®Google Scholar
• Richter B, Koller L, Hohensinner PJ, et al. (2013). A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 168:1251–7
   PubMed Web of Science ®Google Scholar
• Santhanakrishnan R, Chong JP, Ng TP, et al. (2012). Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14:1338–47
   PubMed Web of Science ®Google Scholar
• Sato Y, Fujiwara H, Takatsu Y. (2012). Cardiac troponin and heart failure in the era of high-sensitivity assays. J Cardiol 60:160–7
   PubMed Web of Science ®Google Scholar
• Shah RV, Truong QA, Gaggin HK, et al. (2012). Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33:2197–205
   PubMed Web of Science ®Google Scholar
• Sharma UC, Pokharel S, van Brakel TJ, et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–8
   PubMed Web of Science ®Google Scholar
• Siemelink MA, Zeller T. (2014). Biomarkers of coronary artery disease: the promise of the transcriptome. Curr Cardiol Rep 16:513--23
   PubMedGoogle Scholar
• Thum T. (2014). Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 11:655–63
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. (2012). Third universal definition of myocardial infarction. Circulation 126:2020–35
   PubMed Web of Science ®Google Scholar
• Tschope C, Kasner M, Westermann D, et al. (2005). The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26:2277–84
   PubMed Web of Science ®Google Scholar
• van der Velde AR, Gullestad L, Ueland T, et al. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6:219–26
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL Jr. (2012). Emerging biomarkers in heart failure. Clin Chem 58:127–38
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–24
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. (2013). B-type natriuretic Peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61:1498–506
   PubMed Web of Science ®Google Scholar
• Wang TJ, Levy D, Benjamin EJ, Vasan RS. (2003). The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138:907–16
   PubMed Web of Science ®Google Scholar
• Wang TJ, Wollert KC, Larson MG, et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126:1596–604
   PubMed Web of Science ®Google Scholar
• Westermann D, Kasner M, Steendijk P, et al. (2008). Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117:2051--60
   Google Scholar
• Westermann D, Lindner D, Kasner M, et al. (2011a). Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44--52
   Google Scholar
• Westermann D, Savvatis K, Lindner D, et al. (2011b). Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 124:2082--93
   Google Scholar
• Wild PS, Schnabel RB, Lubos E, et al. (2012). Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem 58:226–36
   PubMed Web of Science ®Google Scholar
• Xuan W, Liao Y, Chen B, et al. (2011). Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 92:385–93
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–239
   PubMed Web of Science ®Google Scholar